47087-2 |
Angiotensinogen |
SCnc |
Plas |
Pt |
Qn |
|
|
ACTIVE |
Angiotensinogen [Moles/volume] in Plasma |
|
MIN |
DefinitionDescription |
|
|
pmol/L |
|
|
|
|
|
|
CHEM |
|
47087-2 |
|
|
|
|
Both |
|
|
|
0 |
Angiotensinogen Plas-sCnc |
|
|
|
N |
|
Chemistry; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Substance concentration |
2.7 |
2.19 |
|
|
|
|
|
|
|
pmol/L |
|
|
|
0 |
47088-0 |
Delta aminolevulinate |
SCnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Delta aminolevulinate [Moles/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
CHEM |
|
47088-0 |
|
|
|
|
Both |
|
|
|
0 |
D-ALA Ser-sCnc |
|
|
|
N |
|
5-ALA; 5-aminolevulinate; 5-aminolevulinic acid; ALA; Aminolevulinic acid; Amnolev; Amnolevuunc; Chemistry; D-ALA; Delta-ala; Delta-aminolevulinic acid; Hematology; Heme; Level; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR; Substance concentration |
2.7 |
2.19 |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
47089-8 |
Indicans |
SRat |
Urine |
24H |
Qn |
|
|
ACTIVE |
Indicans [Moles/time] in 24 hour Urine |
|
MIN |
DefinitionDescription |
|
|
umol/24 H |
|
|
|
|
|
|
CHEM |
|
47089-8 |
|
|
|
|
Both |
|
|
|
0 |
Indicans 24h Ur-sRate |
|
|
|
N |
|
1 day; 24 hours; 24HR; Chemistry; Indoxyl sulfate; QNT; Quan; Quant; Quantitative; sRate; Substance Rate; UA; UR; Urn |
2.7 |
2.19 |
|
|
|
|
|
|
|
umol/(24.h) |
|
|
|
0 |
4709-2 |
HLA-A69(28) |
PrThr |
Bld/Tiss^Donor |
Pt |
Ord |
|
|
ACTIVE |
HLA-A69(28) [Presence] in Donor |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4709-2 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-A69(28) Donr Ql |
|
|
|
|
|
Blood; Donr; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld^donor' to 'Bld/Tiss^donor' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
47090-6 |
Indicans/Creatinine |
SRto |
Urine |
24H |
Qn |
|
|
ACTIVE |
Indicans/Creatinine [Molar ratio] in 24 hour Urine |
|
MIN |
DefinitionDescription |
|
|
mmol/mol;umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
47090-6 |
|
|
|
|
Both |
|
|
|
0 |
Indicans/Creat 24h Ur-sRto |
|
|
|
N |
|
1 day; 24 hours; 24HR; Chemistry; CR; Crea; Creat; Indoxyl sulfate; QNT; Quan; Quant; Quantitative; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.7 |
2.19 |
|
|
|
|
|
|
|
mmol/mol{creat} |
|
|
|
0 |
47091-4 |
Methylmalonate |
SRat |
Urine |
24H |
Qn |
|
|
ACTIVE |
Methylmalonate [Moles/time] in 24 hour Urine |
|
MIN |
DefinitionDescription |
|
|
nmol/d |
|
|
|
|
|
|
CHEM |
|
47091-4 |
|
|
|
|
Both |
|
|
|
0 |
Methylmalonate 24h Ur-sRate |
|
|
|
N |
|
1 day; 24 hours; 24HR; Chemistry; Methylmalonic acid; Methylmalonic Acidemia; MMA; Propionic acidemia; QNT; Quan; Quant; Quantitative; sRate; Substance Rate; UA; UR; Urn |
2.7 |
2.19 |
|
|
|
|
|
|
|
nmol/(24.h) |
|
|
|
0 |
47092-2 |
Natriuretic peptide.B |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Natriuretic peptide B [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
pmol/L |
|
|
|
|
|
|
CHEM |
|
47092-2 |
|
|
|
|
Both |
|
|
|
0 |
BNP SerPl-sCnc |
|
|
|
N |
|
Beta Natriuretic Peptide; BNP; Brain Natriuretic Peptide; B-type natriuretic peptide; Cardio; Cardiology; Chemistry; Heart Disease; Level; Natriutietic peptide.B; Pept; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.73 |
2.19 |
|
|
|
|
|
|
|
pmol/L |
|
|
|
0 |
47093-0 |
Parathyrin.biointact |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
DISCOURAGED |
Parathyrin.biointact [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
pmol/L |
|
|
|
|
|
|
CHEM |
|
47093-0 |
|
|
|
|
Both |
|
|
|
0 |
PTH-Biointact SerPl-sCnc |
|
|
|
N |
|
Bioactive parathyrin; Chemistry; Level; Parathormone; Parathyroid hormone; Pl; Plasma; Plsm; Point in time; PTH; PTH-Biointact; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.7 |
2.19 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
47094-8 |
Calciferol |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Calciferol (Vit D2) [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
pmol/L |
|
|
|
|
|
|
CHEM |
|
47094-8 |
|
|
|
|
Both |
|
|
|
0 |
Vitamin D2 SerPl-sCnc |
|
|
|
N |
|
Activated ergosterol; C28H43OH; Chemistry; Ercalciol; Ergocalciferol; Level; Pl; Plasma; Plsm; Point in time; Pro vitamin D; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; Viosterol; Vit D 1 25 hydroxy; Vit D2; Vitamin D2 |
2.73 |
2.19 |
|
|
|
|
|
|
|
pmol/L |
|
|
|
0 |
47095-5 |
Acetaminophen |
SCnc |
Gast fld |
Pt |
Qn |
|
|
ACTIVE |
Acetaminophen [Moles/volume] in Gastric fluid |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
47095-5 |
|
|
|
|
Both |
|
|
|
0 |
APAP Gast-sCnc |
|
|
|
N |
|
ACET; Acetamidophenol; Acetaminoph; Acetominophen; Addiction; APAP; c209; C55; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GAST; Gastric contents; Gastric fluid; Hepatology; Hydroxyacetanilide; Illicit; Level; Liver; N-(4-Hydroxyphenyl)acetanilide; N-Acetyl-p-aminophenol; p-Acetamidophenol; Paracetamol; p-Hydroxyacetanilide; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; Substance concentration; Tylenol; u209 |
2.7 |
2.19 |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
47096-3 |
Aluminum |
SCnc |
RBC |
Pt |
Qn |
|
|
ACTIVE |
Aluminum [Moles/volume] in Red Blood Cells |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
DRUG/TOX |
|
47096-3 |
|
|
|
|
Both |
|
|
|
0 |
Aluminum RBC-sCnc |
|
|
|
N |
|
AL; Aluminium; DRUG/TOXICOLOGY; Drugs; Erythrocytes; Level; Point in time; QNT; Quan; Quant; Quantitative; Random; Red blood cells; Red blood corpusles; Substance concentration |
2.7 |
2.19 |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
47097-1 |
carBAMazepine 10,11-Epoxide.free |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Carbamazepine 10,11-epoxide free [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
47097-1 |
|
|
|
|
Both |
|
|
|
0 |
Carbamazepine EP Free SerPl-sCnc |
|
|
|
N |
|
Carbamazapine; Carbamazepine EP; Carbamazepine EP Free; Carbamazepine metabolite; Carbamezapine; Carbazepine; CRBM; DRUG/TOXICOLOGY; Drugs; Epitol; FR; Level; Neuro; Neurology; Non-protein bound; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; Tegretol; Teril |
2.7 |
2.19 |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
47098-9 |
Chromium |
SCnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
Chromium [Moles/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
DRUG/TOX |
|
47098-9 |
|
|
|
|
Both |
|
|
|
0 |
Cr Fld-sCnc |
|
|
|
N |
|
B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; c609; Chrome; CR; DRUG/TOXICOLOGY; Drugs; Fl; Fld; FLU; Fluid; Level; Point in time; QNT; Quan; Quant; Quantitative; Random; Substance concentration |
2.75 |
2.19 |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
47099-7 |
Chromium |
SCnc |
Urine |
24H |
Qn |
|
|
ACTIVE |
Chromium [Moles/volume] in 24 hour Urine |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
DRUG/TOX |
|
47099-7 |
|
|
|
|
Both |
|
|
|
0 |
Cr 24h Ur-sCnc |
|
|
|
N |
|
1 day; 24 hours; 24HR; c609; Chrome; CR; DRUG/TOXICOLOGY; Drugs; Level; QNT; Quan; Quant; Quantitative; Substance Concentration; UA; UR; Urn |
2.75 |
2.19 |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
471-3 |
sulfiSOXAZOLE |
Susc |
Isolate |
Pt |
Qn |
MLC |
|
ACTIVE |
sulfiSOXAZOLE [Susceptibility] by Minimum lethal concentration (MLC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
471-3 |
|
MLC |
|
|
Observation |
|
|
|
0 |
Sulfisoxaz Islt MLC |
|
|
|
Y |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Gantrisin; ID; Infectious Disease; InfectiousDisease; Islt; Isol; MBC; Minimum bactericidal concentration; Minimum lethal concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Sulfizole; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.19 |
1 |
|
|
|
|
|
|
|
|
|
|
|
0 |
4710-0 |
HLA-A69(28) |
PrThr |
Bld/Tiss |
Pt |
Ord |
|
|
ACTIVE |
HLA-A69(28) [Presence] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4710-0 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-A69(28) Ql |
|
|
|
|
|
Blood; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld' to 'Bld/Tiss' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
47100-3 |
Copper |
SCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Copper [Moles/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
47100-3 |
|
|
|
|
Both |
|
|
|
0 |
Copper Bld-sCnc |
|
|
|
N |
|
Blood; Cu; DRUG/TOXICOLOGY; Drugs; Level; Point in time; QNT; Quan; Quant; Quantitative; Random; Substance concentration; WB; Whole blood |
2.7 |
2.19 |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
47101-1 |
Copper |
SCnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
Copper [Moles/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
47101-1 |
|
|
|
|
Both |
|
|
|
0 |
Copper Fld-sCnc |
|
|
|
N |
|
B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Cu; DRUG/TOXICOLOGY; Drugs; Fl; Fld; FLU; Fluid; Level; Point in time; QNT; Quan; Quant; Quantitative; Random; Substance concentration |
2.7 |
2.19 |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
47102-9 |
Copper |
SCnc |
RBC |
Pt |
Qn |
|
|
ACTIVE |
Copper [Moles/volume] in Red Blood Cells |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
47102-9 |
|
|
|
|
Both |
|
|
|
0 |
Copper RBC-sCnc |
|
|
|
N |
|
Cu; DRUG/TOXICOLOGY; Drugs; Erythrocytes; Level; Point in time; QNT; Quan; Quant; Quantitative; Random; Red blood cells; Red blood corpusles; Substance concentration |
2.7 |
2.19 |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
47103-7 |
Copper |
SCnt |
Hair |
Pt |
Qn |
|
|
ACTIVE |
Copper [Moles/mass] in Hair |
|
MIN |
DefinitionDescription |
|
|
umol/g |
|
|
|
|
|
|
DRUG/TOX |
|
47103-7 |
|
|
|
|
Both |
|
|
|
0 |
Copper Hair-sCnt |
|
|
|
N |
|
Cu; DRUG/TOXICOLOGY; Drugs; Har; Point in time; QNT; Quan; Quant; Quantitative; Random; Substance content |
2.7 |
2.19 |
|
|
|
|
|
|
|
umol/g |
|
|
|
0 |
47104-5 |
Doxepin |
SCnc |
Gast fld |
Pt |
Qn |
|
|
ACTIVE |
Doxepin [Moles/volume] in Gastric fluid |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
47104-5 |
|
|
|
|
Both |
|
|
|
0 |
Doxepin Gast-sCnc |
|
|
|
N |
|
Adapin; Aponal; Dox; Doxpin; DRUG/TOXICOLOGY; Drugs; GAST; Gastric contents; Gastric fluid; Level; Point in time; QNT; Quan; Quant; Quantitative; Random; Sinequan; Substance concentration |
2.7 |
2.19 |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
47105-2 |
ePHEDrine |
PrThr |
Gast fld |
Pt |
Ord |
|
|
ACTIVE |
ePHEDrine [Presence] in Gastric fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
47105-2 |
|
|
|
|
Both |
|
|
|
0 |
Ephedrin Gast Ql |
|
|
|
N |
|
Addiction; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Ectasule; GAST; Gastric contents; Gastric fluid; Illicit; Ordinal; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Screen |
2.56 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
47106-0 |
ePHEDrine |
PrThr |
Ser/Plas |
Pt |
Ord |
|
|
ACTIVE |
ePHEDrine [Presence] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
47106-0 |
|
|
|
|
Both |
|
|
|
0 |
Ephedrin SerPl Ql |
|
|
|
N |
|
Addiction; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Ectasule; Illicit; Ordinal; Pl; Plasma; Plsm; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.56 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
47107-8 |
Ethanol |
SCnc |
Gast fld |
Pt |
Qn |
|
|
ACTIVE |
Ethanol [Moles/volume] in Gastric fluid |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
DRUG/TOX |
|
47107-8 |
|
|
|
|
Both |
|
|
|
0 |
Ethanol Gast-sCnc |
|
|
|
N |
|
Alc; Alcohol; DRUG/TOXICOLOGY; Drugs; Ethyl alcohol; EtOH; GAST; Gastric contents; Gastric fluid; Level; Point in time; QNT; Quan; Quant; Quantitative; Random; Substance concentration |
2.7 |
2.19 |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
47108-6 |
Furosemide |
PrThr |
Gast fld |
Pt |
Ord |
|
|
ACTIVE |
Furosemide [Presence] in Gastric fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
47108-6 |
|
|
|
|
Both |
|
|
|
0 |
Furosemide Gast Ql |
|
|
|
N |
|
c210; DRUG/TOXICOLOGY; Drugs; Furj; GAST; Gastric contents; Gastric fluid; LASIX; LASJ; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen |
2.56 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |